Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of BMS-690514 in Previously Gefitinib/Erlotinib-Treated EGFR-Positive NSCLC
jRCT2080221239Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BMS-690514 in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb.
02
Drugs
BMS-690514
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221239.